Allogeneic blood stem cell transplantation in advanced hematologic cancers

D. Przepiorka, P. Anderlini, C. Ippoliti, I. Khouri, T. Fietz, P. Thall, R. Mehra, S. Giralt, J. Gajewski, A. B. Deisseroth, K. Cleary, R. Champlin, K. Van Besien, B. Andersson, M. Körbling

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

Allogeneic bone marrow transplantation for advanced hematologic cancer is associated with a high risk of early treatment-related morbidity and mortality. To determine the short-term benefits of allogeneic blood stem cell transplants when compared to bone marrow transplants, we reviewed outcomes of 74 adults with advanced hematologic cancer transplanted from HLA-matched related donors after conditioning with thiotepa, busulfan and cyclophosphamide. There were three cohorts: group 1 received bone marrow transplants with cyclosporine (CsA) and methotrexate (MTX) for GVHD prophylaxis; group 2 received bone marrow transplants with CsA and methylprednisolone (MP); and group 3 received blood stem cells with CsA and MP. All patients received filgrastim post-transplant, Median times (range) to neutrophils ≤ 0.5 x 109/l were 17 (8-30), 9 (8-16) and 10 (8-13) days post-transplant, and to platelets ≤ 20 x 109/l were 28 (14-100+), 19 (13-100+) and 14 (9-86) days post-transplant for groups 1, 2 and respectively (P <0.05 only for group 1 vs group 3 for both outcomes). Blood stem cell recipients had the least regimen-related toxicity, fewest early deaths and earliest discharge. There was no significant difference acute GVHD between the three groups. One hundred and eighty-day survivals (95% CI) were 53% (35-72%), 32% (10-53%), and 68% (49-87%) for groups 1, 2 and 3, respectively (P <0.05 only for group 2 vs group 3). For allogeneic transplantation, use of blood stem cell grafts has substantial advantages over marrow grafts.

Original languageEnglish (US)
Pages (from-to)455-460
Number of pages6
JournalBone Marrow Transplantation
Volume19
Issue number5
StatePublished - Mar 1 1997
Externally publishedYes

Fingerprint

Stem Cell Transplantation
Blood Cells
Transplants
Neoplasms
Stem Cells
Bone Marrow
Homologous Transplantation
Methylprednisolone
Thiotepa
Busulfan
Bone Marrow Transplantation
Methotrexate
Cyclophosphamide
Cyclosporine
Neutrophils
Blood Platelets
Tissue Donors
Morbidity
Survival
Mortality

Keywords

  • Allogeneic blood stem cell transplant
  • Leukemia
  • Treatment-related mortality

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Przepiorka, D., Anderlini, P., Ippoliti, C., Khouri, I., Fietz, T., Thall, P., ... Körbling, M. (1997). Allogeneic blood stem cell transplantation in advanced hematologic cancers. Bone Marrow Transplantation, 19(5), 455-460.

Allogeneic blood stem cell transplantation in advanced hematologic cancers. / Przepiorka, D.; Anderlini, P.; Ippoliti, C.; Khouri, I.; Fietz, T.; Thall, P.; Mehra, R.; Giralt, S.; Gajewski, J.; Deisseroth, A. B.; Cleary, K.; Champlin, R.; Van Besien, K.; Andersson, B.; Körbling, M.

In: Bone Marrow Transplantation, Vol. 19, No. 5, 01.03.1997, p. 455-460.

Research output: Contribution to journalArticle

Przepiorka, D, Anderlini, P, Ippoliti, C, Khouri, I, Fietz, T, Thall, P, Mehra, R, Giralt, S, Gajewski, J, Deisseroth, AB, Cleary, K, Champlin, R, Van Besien, K, Andersson, B & Körbling, M 1997, 'Allogeneic blood stem cell transplantation in advanced hematologic cancers', Bone Marrow Transplantation, vol. 19, no. 5, pp. 455-460.
Przepiorka D, Anderlini P, Ippoliti C, Khouri I, Fietz T, Thall P et al. Allogeneic blood stem cell transplantation in advanced hematologic cancers. Bone Marrow Transplantation. 1997 Mar 1;19(5):455-460.
Przepiorka, D. ; Anderlini, P. ; Ippoliti, C. ; Khouri, I. ; Fietz, T. ; Thall, P. ; Mehra, R. ; Giralt, S. ; Gajewski, J. ; Deisseroth, A. B. ; Cleary, K. ; Champlin, R. ; Van Besien, K. ; Andersson, B. ; Körbling, M. / Allogeneic blood stem cell transplantation in advanced hematologic cancers. In: Bone Marrow Transplantation. 1997 ; Vol. 19, No. 5. pp. 455-460.
@article{5b447c7886d346d392e6dac6b2c56f40,
title = "Allogeneic blood stem cell transplantation in advanced hematologic cancers",
abstract = "Allogeneic bone marrow transplantation for advanced hematologic cancer is associated with a high risk of early treatment-related morbidity and mortality. To determine the short-term benefits of allogeneic blood stem cell transplants when compared to bone marrow transplants, we reviewed outcomes of 74 adults with advanced hematologic cancer transplanted from HLA-matched related donors after conditioning with thiotepa, busulfan and cyclophosphamide. There were three cohorts: group 1 received bone marrow transplants with cyclosporine (CsA) and methotrexate (MTX) for GVHD prophylaxis; group 2 received bone marrow transplants with CsA and methylprednisolone (MP); and group 3 received blood stem cells with CsA and MP. All patients received filgrastim post-transplant, Median times (range) to neutrophils ≤ 0.5 x 109/l were 17 (8-30), 9 (8-16) and 10 (8-13) days post-transplant, and to platelets ≤ 20 x 109/l were 28 (14-100+), 19 (13-100+) and 14 (9-86) days post-transplant for groups 1, 2 and respectively (P <0.05 only for group 1 vs group 3 for both outcomes). Blood stem cell recipients had the least regimen-related toxicity, fewest early deaths and earliest discharge. There was no significant difference acute GVHD between the three groups. One hundred and eighty-day survivals (95{\%} CI) were 53{\%} (35-72{\%}), 32{\%} (10-53{\%}), and 68{\%} (49-87{\%}) for groups 1, 2 and 3, respectively (P <0.05 only for group 2 vs group 3). For allogeneic transplantation, use of blood stem cell grafts has substantial advantages over marrow grafts.",
keywords = "Allogeneic blood stem cell transplant, Leukemia, Treatment-related mortality",
author = "D. Przepiorka and P. Anderlini and C. Ippoliti and I. Khouri and T. Fietz and P. Thall and R. Mehra and S. Giralt and J. Gajewski and Deisseroth, {A. B.} and K. Cleary and R. Champlin and {Van Besien}, K. and B. Andersson and M. K{\"o}rbling",
year = "1997",
month = "3",
day = "1",
language = "English (US)",
volume = "19",
pages = "455--460",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Allogeneic blood stem cell transplantation in advanced hematologic cancers

AU - Przepiorka, D.

AU - Anderlini, P.

AU - Ippoliti, C.

AU - Khouri, I.

AU - Fietz, T.

AU - Thall, P.

AU - Mehra, R.

AU - Giralt, S.

AU - Gajewski, J.

AU - Deisseroth, A. B.

AU - Cleary, K.

AU - Champlin, R.

AU - Van Besien, K.

AU - Andersson, B.

AU - Körbling, M.

PY - 1997/3/1

Y1 - 1997/3/1

N2 - Allogeneic bone marrow transplantation for advanced hematologic cancer is associated with a high risk of early treatment-related morbidity and mortality. To determine the short-term benefits of allogeneic blood stem cell transplants when compared to bone marrow transplants, we reviewed outcomes of 74 adults with advanced hematologic cancer transplanted from HLA-matched related donors after conditioning with thiotepa, busulfan and cyclophosphamide. There were three cohorts: group 1 received bone marrow transplants with cyclosporine (CsA) and methotrexate (MTX) for GVHD prophylaxis; group 2 received bone marrow transplants with CsA and methylprednisolone (MP); and group 3 received blood stem cells with CsA and MP. All patients received filgrastim post-transplant, Median times (range) to neutrophils ≤ 0.5 x 109/l were 17 (8-30), 9 (8-16) and 10 (8-13) days post-transplant, and to platelets ≤ 20 x 109/l were 28 (14-100+), 19 (13-100+) and 14 (9-86) days post-transplant for groups 1, 2 and respectively (P <0.05 only for group 1 vs group 3 for both outcomes). Blood stem cell recipients had the least regimen-related toxicity, fewest early deaths and earliest discharge. There was no significant difference acute GVHD between the three groups. One hundred and eighty-day survivals (95% CI) were 53% (35-72%), 32% (10-53%), and 68% (49-87%) for groups 1, 2 and 3, respectively (P <0.05 only for group 2 vs group 3). For allogeneic transplantation, use of blood stem cell grafts has substantial advantages over marrow grafts.

AB - Allogeneic bone marrow transplantation for advanced hematologic cancer is associated with a high risk of early treatment-related morbidity and mortality. To determine the short-term benefits of allogeneic blood stem cell transplants when compared to bone marrow transplants, we reviewed outcomes of 74 adults with advanced hematologic cancer transplanted from HLA-matched related donors after conditioning with thiotepa, busulfan and cyclophosphamide. There were three cohorts: group 1 received bone marrow transplants with cyclosporine (CsA) and methotrexate (MTX) for GVHD prophylaxis; group 2 received bone marrow transplants with CsA and methylprednisolone (MP); and group 3 received blood stem cells with CsA and MP. All patients received filgrastim post-transplant, Median times (range) to neutrophils ≤ 0.5 x 109/l were 17 (8-30), 9 (8-16) and 10 (8-13) days post-transplant, and to platelets ≤ 20 x 109/l were 28 (14-100+), 19 (13-100+) and 14 (9-86) days post-transplant for groups 1, 2 and respectively (P <0.05 only for group 1 vs group 3 for both outcomes). Blood stem cell recipients had the least regimen-related toxicity, fewest early deaths and earliest discharge. There was no significant difference acute GVHD between the three groups. One hundred and eighty-day survivals (95% CI) were 53% (35-72%), 32% (10-53%), and 68% (49-87%) for groups 1, 2 and 3, respectively (P <0.05 only for group 2 vs group 3). For allogeneic transplantation, use of blood stem cell grafts has substantial advantages over marrow grafts.

KW - Allogeneic blood stem cell transplant

KW - Leukemia

KW - Treatment-related mortality

UR - http://www.scopus.com/inward/record.url?scp=0031040240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031040240&partnerID=8YFLogxK

M3 - Article

C2 - 9052911

AN - SCOPUS:0031040240

VL - 19

SP - 455

EP - 460

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 5

ER -